IP Library Granted Patent US 10,329,327
Granted Patent B2
US 10,329,327 · App. 13/991,842 · Granted Jun 25, 2019

Tricalcium phosphate binding peptides and uses thereof

Inventors: Luis Alvarez (Frederick, MD); Linda G. Griffith (Cambridge, MA); Yadir Guerrero (Cambridge, MA); Linda Stockdale (Providence, RI); Jaime Rivera (Brookline, MA)
Assignee: Massachusetts Institute of Technology
C07K7/08A61K35/28A61K38/10A61K38/1808A61L27/12A61L27/3834A61L27/3847A61L27/54A61L27/56C07K14/485C12N5/0662A61L2300/25A61L2300/252A61L2300/414A61L2400/08A61L2400/18A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,327
App. No.
13/991,842
Granted
Jun 25, 2019
Kind
B2
Abstract

The invention is directed to a composition comprising all or a portion of a beta-tricalcium phosphate (β-TCP) bound to all or a portion of a β-TCP binding peptide and methods of use thereof.

Claims (19)

1. A composition comprising a beta-tricalcium phosphate (β-TCP) non-covalently bound to a concatenated multimer of two or more β-TCP binding peptides, wherein at least one of the β-TCP binding peptides comprises LLADTTHHRPWT (SEQ ID NO: 1), and binds to β-TCP with a Kd of 3.5 μM or lower.

2. The composition of claim 1 wherein the β-TCP is a β-TCP scaffold.

3. The composition of claim 2 wherein the scaffold further comprises polylactide-co-glycolide.

4. The composition of claim 2 wherein the scaffold further comprises one or more porogens.

5. The composition of claim 4 wherein the porogen is sucrose.

6. The composition of claim 1 wherein the composition is a concatenated multimer comprising two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty repeats of a β-TCP binding peptide bound to the β-TCP.

7. The composition of claim 1 wherein at least one of the β-TCP binding peptides comprises the amino acid sequence: GQVLPTTTPSSP (SEQ ID NO: 2), VPQHPYPVPSHK (SEQ ID NO: 3), HNMAPATLHPLP (SEQ ID NO: 4), QSFASLTNPRVL (SEQ ID NO: 5), HTTPTTTYAAPP (SEQ ID NO: 6), QYGVVSHLTHTP (SEQ ID NO: 7), TMSNPITSLISV (SEQ ID NO: 8), IGRISTHAPLHP (SEQ ID NO: 9), MNDPSPWLRSPR (SEQ ID NO: 10), QSLGSMFQEGHR (SEQ ID NO: 11), KPLFTRYGDVAI (SEQ ID NO: 12), MPFGARILSLPN (SEQ ID NO: 13), QLQLSNSMSSLS (SEQ ID NO: 14), TMNMPAKIFAAM (SEQ ID NO: 15), EPTKEYTTSYHR (SEQ ID NO: 16), DLNELYLRSLRA (SEQ ID NO: 17), DYDSTHGAVFRL (SEQ ID NO: 18), SKHERYPQSPEM (SEQ ID NO: 19), HTHSSDGSLLGN (SEQ ID NO: 20), NYDSMSEPRSHG (SEQ ID NO: 21), ANPIISVQTAMD (SEQ ID NO: 22) or a combination thereof.

8. The composition of claim 1 wherein one or more of the β-TCP binding peptides is fused to one or more additional peptides or proteins.

9. The composition of claim 8 wherein each β-TCP binding peptide is fused to each additional peptide or protein via a linker.

10. The composition of claim 8 wherein one or more of the β-TCP binding peptides is fused to all or a portion of a growth factor or a cytokine.

11. The composition of claim 8 wherein the one or more additional peptides or proteins is an epidermal growth factor (EGF), a platelet-derived growth factor (PDGF), a bone morphogenic protein 2 (BMP-2), BMP-4, BMP-7, osteogenic protein (OP-1), collagen binding protein or a combination thereof.

12. The composition of claim 9 wherein the linker is a coiled coil linker.

13. The composition of claim 12 wherein the coiled coil linker is a leucine zipper.

14. The composition of claim 1 wherein the composition further comprises mesenchymal stem cells.

15. A pharmaceutical composition comprising the composition of claim 1 .

16. The composition of claim 2 , wherein the (β-TCP scaffold is in the shape of a cross having at least one dimension that is 3 mm in size.

17. The composition of claim 16 , wherein the cross has the dimensions 5 mm×5 mm×3 mm.

18. The composition of claim 2 , wherein the (β-TCP scaffold comprises granulated β-TCP powder that is at least 95% β-TCP.

19. The composition of claim 1 , wherein each β-TCP binding peptide comprises LLADTTHHRPWT (SEQ ID NO: 1), and binds to (β-TCP with a Kd of 3.5 μM or lower.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: ALVAREZ, LUIS
Reel/Frame 053228/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: ALVAREZ, LUIS
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 053228/0557 →
CONFIRMATORY LICENSE Recorded May 21, 2015
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035749/0243 →
Continuity (2)
Provisional Application 61419946 · Dec 6, 2010
Related Publication 20140037593A1 · Feb 6, 2014
Cited By (1)
US 12,264,187